Gracell Raises $209 Million in US IPO for Novel CAR-T Therapies
publication date: Jan 8, 2021
Gracell Biotech of Suzhou completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Gracell set out to address the difficulties presented by previous cell therapies, including complex manufacture, lack of off-the-shelf products and the short duration of efficacy. Gracell uses two platforms for discovery: FasTCAR, which manufactures autologous CAR-T products in 22-36 hours (rather than two to six weeks); and TruUCAR, which offers off-the-shelf CAR-T products. Gracell has a market cap of $1.7 billion after climbing 38% in early trading. More details....
Stock Symbol: (NSDQ:GRCL)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.